Scientech Research LLC Boosts Position in DexCom, Inc. $DXCM

Key Points

• Scientech Research LLC increased its stake in DexCom, Inc. by 200% during the first quarter, owning 22,226 shares worth approximately $1.52 million.
• Numerous hedge funds have also significantly boosted their positions in DexCom, with 97.75% of the stock owned by institutional investors.
• DexCom reported earnings of $0.48 per share in its latest quarter, surpassing estimates and showing a 15.2% revenue growth year-over-year.

Scientech Research LLC lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 200.0% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 22,226 shares of the medical device company's stock after buying an additional 14,817 shares during the quarter. Scientech Research LLC's holdings in DexCom were worth $1,518,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in DXCM. Golden State Wealth Management LLC grew its holdings in DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after acquiring an additional 264 shares in the last quarter. Zions Bancorporation National Association UT purchased a new stake in shares of DexCom during the 1st quarter worth $27,000. Heck Capital Advisors LLC acquired a new position in shares of DexCom during the fourth quarter worth $38,000. Alpine Bank Wealth Management purchased a new position in DexCom in the first quarter valued at $40,000. Finally, Private Trust Co. NA raised its stake in DexCom by 99.4% in the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock valued at $46,000 after buying an additional 335 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on DXCM shares. UBS Group increased their price objective on DexCom from $105.00 to $106.00 and gave the company a "buy" rating in a report on Thursday, July 31st. Wall Street Zen lowered shares of DexCom from a "strong-buy" rating to a "buy" rating in a research note on Sunday, August 10th. Citigroup restated a "buy" rating and set a $102.00 price objective (up previously from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Morgan Stanley upped their target price on shares of DexCom from $82.00 to $89.00 and gave the company an "equal weight" rating in a report on Tuesday, July 15th. Finally, Mizuho increased their target price on shares of DexCom from $95.00 to $100.00 and gave the company an "outperform" rating in a research report on Wednesday, July 16th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, DexCom presently has a consensus rating of "Moderate Buy" and a consensus target price of $99.89.

Insider Activity at DexCom

In other news, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $81.06, for a total transaction of $222,915.00. Following the completion of the transaction, the director directly owned 51,121 shares of the company's stock, valued at approximately $4,143,868.26. This represents a 5.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Sadie Stern sold 1,466 shares of DexCom stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $88.99, for a total value of $130,459.34. Following the completion of the sale, the executive vice president owned 106,689 shares in the company, valued at approximately $9,494,254.11. This trade represents a 1.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 15,237 shares of company stock worth $1,263,480 in the last three months. 0.32% of the stock is currently owned by corporate insiders.

DexCom Stock Performance

DXCM traded up $0.02 during trading on Friday, hitting $76.02. The stock had a trading volume of 946,229 shares, compared to its average volume of 3,924,496. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $93.25. The firm has a market capitalization of $29.81 billion, a P/E ratio of 52.94, a PEG ratio of 1.59 and a beta of 1.48. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The company's 50-day moving average price is $81.01 and its 200 day moving average price is $78.80.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.03. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business's quarterly revenue was up 15.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.